Navigation Links
Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference

Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference -- POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference


POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the Newsmakers in the Biotech Industry Conference in New York on October 22, 2010 at 10:30 a.m. EDT.

A live audio webcast and replay of this presentation may be accessed at and on the Transcept Investor webpage at

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at:

Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release are forward-looking statements. An example of such a statement is our plan to begin a Phase 2, double-blind, placebo-controlled study of TO-2061 in 2011. Transcept may not actually carryout this plan. Various important factors could cause actual events to differ materially from the forward-looking statements that Transcept makes, include the outcomes from planned Phase 1 studies of TO-2061 and discussions with the FDA about our plan to move forward with the Phase 2 study; dependence on third parties to manufacture TO-2061 and carry-out the planned study; our success in efforts to seek approval for Intermezzo®, our lead product candidate, and the business of Transcept generally. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law. Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510)

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Present at BIO Investor Forum
2. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
3. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
4. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
5. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
6. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
9. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Post Your Comments:
(Date:10/12/2015)... Center for Innovation announced today that Elizabeth ... th recipient of the CME Group Melamed-Arditti Innovation ... Theranos , to change health care from reactive to proactive, ... care. CME Group will present the award at the eighth ... Naples, Florida , on Tuesday, November 17. ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 ... new market research report "Spirometer Market by Product (Hand-held, Table-top, ... (Hospital, Clinic, Homecare), Application, & Geography - Global Forecast to ... reach USD 858.6 Million by 2020, at a CAGR of ... data Tables and 128 F igures spread th ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver compared ... patients with or without mesothelioma. Surviving Mesothelioma has just posted an article on the ... PhenoPath Laboratories in Seattle and the University of British Columbia found that certain genetic ...
(Date:10/13/2015)... ... October 13, 2015 , ... World Patent Marketing , a vertically ... melting invention that helps people in clearing snow away from the streets and driveways. ... at 3.8% per year," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:10/13/2015)... ... October 13, 2015 , ... With Fall weather approaching and holiday travel season ... Facebook Hair Styler Contest. , Enter to win! , How to Enter:, 1. ... Favorite Hair Style? , 3. Follow us on Instagram @thebeautyplace , 4. Share ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Just under three ... customers, eMarketing Concepts began a $1 promotion – effectively offering all of their services ... and within weeks the company was flooded with phone calls from interested buyers. As ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test for bacterial ... of Gynecology and Obstetrics in Vancouver, BC, Canada. , In a ...
Breaking Medicine News(10 mins):